01st week of 2013 patent applcation highlights part 45 |
Patent application number | Title | Published |
20130004406 | CARBON DIOXIDE RECOVERY SYSTEM AND METHOD OF EXHAUST GAS - Disclosed is a method for recovering carbon dioxide from exhaust gas, more particularly, a method for recovering carbon dioxide from exhaust gas for saving the cost for recovery of carbon dioxide by decreasing energy required for recycling a carbon dioxide absorbent solution. In particular, a circulating solvent, whose heat of vaporization and/or sensible heat is lower than that of a solvent of an absorbent solution introduced to a recycling tower, is supplied to the lower portion of the recycling tower and mixed with the heated absorbent solution. As a result, the pressure inside the recycling tower is maintained so that carbon dioxide released from the absorbent solution is discharged to a storage tank/drum. | 2013-01-03 |
20130004407 | METHOD FOR PREPARING ULTRAFINE TUNGSTEN CARBIDE POWDER - A method for preparing ultrafine powder of tungsten carbide using ultrafine tungsten powder and carbon black as raw materials is provided. The following steps are included: (1) passivation of the ultrafine tungsten powder: passivating the ultrafine tungsten powder under pure carbon dioxide; (2) carbon addition: mixing the ultrafine tungsten powder with carbon black powder after applying cooling water and inert gases; (3) carbonization: synthesizing the bulk tungsten carbide powder at high temperature in a carbonizing stove; (4) crushing and sieving: crushing the bulk tungsten carbide powder, cooling and sieving to obtain the ultrafine powder of tungsten carbide. | 2013-01-03 |
20130004408 | Moderate Temperature Synthesis of Mesoporous Carbon - Methods and composition for preparation of mesoporous carbon material are provided. For example, in certain aspects methods for carbonization and activation at selected temperature ranges are described. Furthermore, the invention provides products prepared therefrom. | 2013-01-03 |
20130004409 | PYROLYSIS AND GASIFICATION SYSTEMS, METHODS, AND RESULTANTS DERIVED THEREFROM - A process and system for the controlled thermal conversion of a carbonaceous feedstock, including: exposing the feedstock to one or more predetermined temperatures and one or more predetermined pressures for one or more predetermined amounts of time in one or more chambers to produce a gas product and a solid product, wherein the gas product includes one or more of methane, carbon monoxide, hydrogen, and one or more noxious chemicals and the solid product includes Carbon; sequestration enabling at least a portion of the Carbon by creating associated Lewis Acid Sites; sequestering at least one of the one or more noxious chemicals in the one or more chambers using the sequestration enabled Carbon; and controlling the constituents of the gas product using feedback, thereby providing a predictable and stable gas product from an unknown and/or variable feedstock. | 2013-01-03 |
20130004410 | METHOD FOR THE PRODUCTION OF GRAPHITE BODIES - The present invention relates to a method for production of graphite bodies. Carbon bodies are formed from a mixture of electric calcined coke particles calcined at a temperature between 1200 and 3000° C. and a binder where the coke particles have sulphur-and nitrogen content varying between 0 and 1.5% by weight and where the coke particles have an average sulphur content less than 0.6% by weight and a nitrogen content of less than 0.6% by weight, baking of the carbon bodies at a temperature between 700 and 1400° C. and graphitizing of the baked carbon bodies at a temperature above 2300° C. | 2013-01-03 |
20130004411 | POLYELECTROLYTE MULTILAYER THIN FILM CATALYST AND METHOD FOR PRODUCING SAME - Disclosed herein is a catalyst, including, in one example: a carrier, a polymer electrolyte multilayer film formed on the carrier, and metal particles dispersed in the polymer electrolyte multilayer film. The catalyst can be easily prepared, and can be used to produce hydrogen peroxide in high yield in the presence of a reaction solvent including no acid promoter. | 2013-01-03 |
20130004412 | SYNTHESIS OF PALLADIUM BASED METAL OXIDES BY SONICATION - Provided herein are aqueous sonolysis methods involving mixing a precursor transition metal salt, with a Pd-water slurry and sonicating the resulting reaction mixture to synthesize the palladium-based transition metal oxides. Also provided herein are palladium-based transition metal oxides. | 2013-01-03 |
20130004413 | OXIDES-BASED MATERIAL, DEVICE, AND PROCESS FOR HYDROGEN STORAGE - A hydrogen storage material comprises an oxide and a hydride that can react with each other reversibly to produce hydrogen gas. A solid state hydrogen storage device and process of producing and storing hydrogen are also described. | 2013-01-03 |
20130004414 | DEVICES AND METHODS FOR REDUCING RADIOLYSIS OF RADIOISOTOPES - Disclosed are microfluidic devices and kits for containing radioisotopes. The devices and kits comprises at least one confining geometry having a cross-section dimension below the beta(+) or beta(−) range of a radioisotope, when containing the radioisotope configured in such a way that that neighboring segments of the confining geometries are isolated from its nearest neighbor such that no measurable kinetic positron energy transfer occurs between the segments when containing the radioisotope. Methods of storage and synthesis of radiopharmaceuticals are also disclosed. In another aspect, the present invention relates to methods of storing radiotracers and synthesizing radiopharmaceuticals, using the aforementioned device. The radiotracers and radiopharmaceuticals comprises | 2013-01-03 |
20130004415 | Joint-Homing Peptides and Uses Thereof - The present invention provides peptides that home to a joint of an animal, wherein said peptide comprises an amino acid motif selected from the group consisting of NQR and ADK. Also provided are methods of treating a subject having an arthritic joint, comprising the step of administering to said subject a pharmacologically effective dose of a composition provided herein. | 2013-01-03 |
20130004416 | Dual Variable Domain Immunoglobulin and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 2013-01-03 |
20130004417 | Gold Coated Lanthanide Nanoparticles - The present invention is directed α-particle emitting nanoparticles that comprise a lanthanide phosphate sequestration shell enclosing an α-emitting-radioisotope-doped lanthanide phosphate core such that the shell allows at least some of the α emissions from the α-emitting radioisotope to pass therethrough and prevents at least some radioactive decay products of the α-emitting radioisotope from exiting the α-particle emitting nanoparticle. Further, such α-particle emitting nanoparticles may be coated with gold and functionalized. Additionally, a method for making and using the same are disclosed. | 2013-01-03 |
20130004418 | INFILTRATION SOLUTION FOR TREATING AN ENAMEL LESION - The invention relates to an infiltration solution of a radiopaque metal compound for treating an enamel lesion, to a kit for dental application, and to the use thereof for preventing and/or treating (sealing) carious enamel lesions. | 2013-01-03 |
20130004419 | Carbonylporphyrins and Uses Thereof - The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity carborane-containing porphyrin compounds with halide, amine, or nitro groups and methods for their use particularly in boron neutron capture therapy (BNCT), X-ray radiation therapy (XRT), and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention is also directed to using these carborane-containing porphyrin compounds in methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET. | 2013-01-03 |
20130004420 | HYPERVALENT RADIOACTIVE ASTATINE OR IODINE COMPOUNDS, AND PREPARATION METHODS THEREOF - The present invention relates to a compound having formula (I): wherein: X is in particular | 2013-01-03 |
20130004421 | RADIOLABELED AFFIBODY MOLECULES - The invention provides a radiolabeled affibody molecule comprising a fragment of an IgG-binding domain of protein A from | 2013-01-03 |
20130004422 | BENZOTHIAZOLE DERIVATIVE COMPOUNDS, COMPOSITIONS AND USES - This invention provides benzothiazole derivative compounds, compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for detecting amyloid deposit(s) and for diagnosing a disease, disorder or condition characterized by amyloid deposit(s). | 2013-01-03 |
20130004423 | POLYAZAMACROCYCLIC COMPOUND, AND A PRODUCTION METHOD AND A BIOMEDICAL USE THEREFOR - According to the present invention, a novel polyazamacrocyclic compound which is used as a bifunctional chelating agent (BFC) can be synthesized selectively and in high yield. The novel polyazamacrocyclic compound synthesized by this method chelates with metals and thus can be conjugated with bioactive molecules such as peptides, and can be used in the diagnosis and treatment of medical conditions. | 2013-01-03 |
20130004424 | METHODS FOR DETERMINING AGENTS TARGETING MENA ISOFORMS AND USES THEREOF FOR DIAGNOSIS AND TREATMENT OF METASTATIC TUMORS - The present invention relates to methods of determining agents that inhibit Mena | 2013-01-03 |
20130004425 | Biomineral and Metal Binding Liposomes, Their Synthesis, and Methods of Use Thereof - Drug carriers, methods of synthesizing, and methods of use thereof are provided. | 2013-01-03 |
20130004426 | ADENOSINE DERIVATIVE FORMULATIONS FOR MEDICAL IMAGING - A stable composition useful for myocardial perfusion imaging contains one or more 2-alkynyladenosine derivatives; and a solvent which is made up of water and hydroxypropyl-β-cyclodextrin. | 2013-01-03 |
20130004427 | TARGETED DENDRIMER-DRUG CONJUGATES - The invention provides for dendrimer conjugates useful for liver-specific delivery of therapeutic agents. The therapeutic agent is associated to the dendrimer through a enzyme-cleavable covalent linkage. | 2013-01-03 |
20130004428 | DIAZABICYCLONONYL OXADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS - This invention relates to diazabicyclononyl oxadiazolyl derivatives, which are found to-be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. Ar | 2013-01-03 |
20130004429 | USE OF A NEUROFILAMENT PEPTIDE FOR THE TREATMENT OF GLIOMA - The present invention provides a new drug to treat malignant glioma, which is the most prevalent type of primary tumor of the central nervous system (CNS). The present invention indeed shows that the isolated NFL-TBS | 2013-01-03 |
20130004430 | FLUORESCENT PHOTOPROBE FOR THE IMAGING OF ENDOTHELIN RECEPTORS - The present invention relates to an endothelin receptor antagonist conjugate of the formula (I) wherein R | 2013-01-03 |
20130004431 | TRANSPORT AGENTS FOR CROSSING THE BLOOD-BRAIN BARRIER AND INTO BRAIN CANCER CELLS AND METHODS OF USE THEREOF - The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from | 2013-01-03 |
20130004432 | MONOCLONAL ANTIBODIES THAT BIND B7H6 AND USES THEREOF - Disclosed are monoclonal antibodies that specifically bind to the B7 family member B7H6, including antibodies capable of inhibiting the interaction of B7H6 with NKp30. Also disclosed are anti-B7H6 antibody-drug conjugates comprising an anti-B7H6 monoclonal antibody conjugated to a therapeutic agent. The anti-B7H6 antibodies and antibody-drug conjugates are useful in methods for exerting therapeutic effects against B7H6-expressing cells, as well as in diagnostic methods for the detection of B7H6 or B7H6-expressing cells. | 2013-01-03 |
20130004433 | PREPARATION OF STABILISED X-RAY DIAGNOSTIC COMPOSITION - The invention relates to a process for the preparation of a diagnostic X-ray composition. The composition comprises a non-ionic X-ray contrast agent in a pharmaceutically acceptable carrier. More particularly, the invention relates to a process for secondary production of X-ray compositions comprising X-ray contrast agents with a high dissolution temperature. When using the process of the invention, precipitation is avoided and degradation of the contrast agent is reduced. The process of the invention includes heat treatment of iodinated X-ray contrast agents at low pH. | 2013-01-03 |
20130004434 | Gastroretentive, Extended Release Composition Of Therapeutic Agent - A gastroretentive, extended release composition which floats and swells at acidic pH prevalent in the stomach. The composition includes a pH dependent graft copolymer, a gellable polymer, a therapeutic agent, a gas generating system and pharmaceutically acceptable ingredients. The disclosed composition is useful to deliver the therapeutic agent within the stomach for an extended period of time. | 2013-01-03 |
20130004435 | AZEOTROPE-LIKE COMPOSITIONS COMPRISING 1-CHLORO-3,3,3-TRIFLUOROPROPENE - The present invention relates, in part, to ternary azeotropic compositions and mixtures including chlorotrifluoropropene, methanol, and a third component selected from isohexane, trans-1,2-dichloroethylene, and petroleum ether. The present invention further relates to ternary azeotropic compositions and mixtures including chlorotrifluoropropene, cyclopentane, and a alcohol selected from methanol, ethanol, and isopropanol. | 2013-01-03 |
20130004436 | Compositions and Methods of Treating and Preventing Lung Cancer and Lymphangioleiomyomatosis - Compositions and methods for treating and preventing cancer, particularly lung cancer, lymphangioleiomyomatosis and asthma are provided. | 2013-01-03 |
20130004437 | NOVEL COMPOUND - The invention relates to novel polyglycerol based UV-filters as well as to topical compositions comprising such novel polyglycerol based UV-filters. Furthermore, the invention relates to the use of such novel polyglycerol based UV-filters to enhance the solubility of butyl methoxydibenzoylmethane or bis-ethylhexyloxyphenol methoxyphenyl triazine in cosmetic oils. | 2013-01-03 |
20130004438 | COSMETIC COMPOSITION COMPRISING A SUPRAMOLECULAR COMPOUND CAPABLE OF ESTABLISHING HYDROGEN BONDS, AND A PARTICULAR ADDITIONAL INGREDIENT - The present invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium, (i) a supramolecular compound that may be obtained by reaction between: —at least one oil bearing at least one nucleophilic reactive function chosen from OH and NH | 2013-01-03 |
20130004439 | Lipo-Phosphated or Lipo-Sulphated Compound, Compositions Comprising It and Topical Uses Thereof - The compound according to the invention has the following developed formula IX: | 2013-01-03 |
20130004440 | PHOTOSTABLE SUNSCREEN COMPOSITION - The present invention relates to photostable sunscreen compositions comprising sunscreens, more particularly to a liquid composition in emulsion or microemulsion format comprising dibenzoylmethane sunscreens. An object of the present invention is to provide photostable compositions comprising dibenzoylmethane sunscreens, wherein the stabilization is brought about by using readily available and inexpensive ingredients. The present inventors have surprisingly found that cosmetic compositions comprising dibenzoylmethane or its derivative can be stabilized in a specific liquid emulsion or microemulsion formulation having specified ingredients in selective amounts. | 2013-01-03 |
20130004441 | NON-AQUEOUS STRUCTURED COMPOSITIONS - Disclosed are non-aqueous compositions capable of forming a gel structure, comprising (a) a low molecular mass N-acyl glutamic acid diamide having a straight-chain alkyl group; (b) a low molecular mass N-acyl glutamic acid diamide having a branched-chain alkyl group; (c) at least one gel-promoting solvent which includes a substituted hydrocarbyl functional siloxane and/or a second, different gel-promoting solvent; (d) at least one active ingredient, and (e) optionally, at least one polyorganosiloxane-containing polymer; wherein the composition has a hardness value ranging from about 30 to about 300 gf, a melting point of about 50° C. or higher. Methods of making and using the compositions are also disclosed. | 2013-01-03 |
20130004442 | STRUCTURED NON-AQUEOUS GEL-FORM CARRIER COMPOSITION - Disclosed are non-aqueous carrier compositions capable of forming a gel structure, having a low molecular mass N-acyl glutamic acid diamide having a straight-chain alkyl group, a low molecular mass N-acyl glutamic acid diamide having a branched-chain alkyl group, at least one gel-promoting solvent, and at least one high molecular mass block copolymer having at least one hard segment and at least one soft segment, and at least one solvent capable of solubilizing the at least one hard segment and/or the at least one soft segment of the block copolymer, at least one oil-soluble polar modified polymer; and at least one solvent capable of solubilizing the at least one oil-soluble polar modified polymer, and optionally at least one active ingredient, wherein the composition has a hardness value ranging from about 30 to about 300 gf, a melting point of about 50° C. or higher, and does not require use of wax as a structuring agent. Methods of making and using the compositions are also disclosed. | 2013-01-03 |
20130004443 | SUNSCREEN FORMULATIONS - Disclosed are stable sunscreen compositions and corresponding methods for their use that are effective in protecting skin from UVA and UVB radiation. The composition uses a combination of ingredients to effectively and stably solubilize sunscreen agents to create a stable formulation. | 2013-01-03 |
20130004444 | COMPOSITION CONTAINING AT LEAST ONE C7 SUGAR FOR ALOPECIA TREATMENT, COSMETIC TREATMENT OF HAIR AND NAILS, AND CARE OF HAIR, EYELASHES, OR NAILS - The present invention relates to a composition including at least one C7 sugar, or derivative from esterification of said sugar, and a pharmaceutically acceptable carrier for treating alopecia. The present invention also relates to a method for cosmetically treating hair and nails, said method being intended to stimulate the growth thereof and/or slow the loss thereof. According to said method, a cosmetic composition including at least one C7 sugar, or derivative from esterification of said sugar, is administered. The present invention finally relates to a method for cosmetic care of hair and/or eyelashes and/or nails. | 2013-01-03 |
20130004445 | ORGANOSILOXANES CONTAINING ESTER DERIVATIVES OF ASCORBIC ACID - Organosiloxanes containing ester derivatives of ascorbic acid are disclosed having the formula (R | 2013-01-03 |
20130004446 | LONG-WEARING NON-AQUEOUS STRUCTURED COLOR COSMETIC - Disclosed are non-aqueous compositions capable of forming a gel structure, containing: (a) a low molecular mass N-acyl glutamic acid diamide having a straight-chain alkyl group; (b) a low molecular mass N-acyl glutamic acid diamide having a branched-chain alkyl group; (c) at least one gel-promoting solvent; (d) at least one film former; (e) at least one volatile solvent capable of solubilizing the film former; and (f) at least one colorant; and (g) a polyorganosiloxane-containing polymer, wherein the composition has a hardness value ranging from about 30 to about 300 gf, a melting point of about 500 C or higher, does not require use of wax as a structuring agent. Methods of making and using the compositions are also disclosed. | 2013-01-03 |
20130004447 | 2,4-DISUBSTITUTED PYRIDINES AS PERFUMING INGREDIENTS - The present invention relates to the field of perfumery. More particularly, it concerns the use as perfuming ingredients of a 2,4-dialkyl-pyridine of formula (I): | 2013-01-03 |
20130004448 | METHOD FOR PREPARING A RECYCLABLE POLYAMIDE POWDER - The present invention relates to a method for preparing a recyclable polyimide powder, said method including the following consecutive steps: a) a step of adding 0.01 to 5 wt % of at least one antioxidant in powder form to a mixture including 20 to 95 wt % of polyamide powder and 5 to 80 wt % of liquid, relative to the weight of said mixture, said polyamide powder having a pH in the range from 3 to 8 and a yellowness index of less than 4, measured according to standard ASTM E 313-05, D1925, said liquid being non-solvent for polyamide at a temperature between 5° C. and the boiling temperature T | 2013-01-03 |
20130004449 | Conditioner And Conditioning Shampoo Compound Containing Pentaerythritol Ester - The invention relates to a cosmetic preparation containing (a) esters of fatty acids having 6 to 12 carbon atoms with pentaerythritol and (b) silicones. | 2013-01-03 |
20130004450 | Protein-Acrylate Copolymer and Hair Conditioning Product Comprising Said Polymer - A protein-acrylate copolymer contains at least one nitrogen containing acrylic monomer. The nitrogen containing acrylic monomer preferably contains a tertiary or quaternary amine group, and particularly a quaternary amine group. The protein-acrylate copolymer can be produced by reacting hydrolysed protein with at least one nitrogen containing acrylic monomer, preferably by free-radical polymerisation. The protein-acrylate copolymer is suitable for use in personal care or cosmetic products, particularly in hair care products where it can increase volume to hair. | 2013-01-03 |
20130004451 | PERSONAL CARE COMPOSITION - A multi-phase personal care composition comprising at least two visually distinct phases in physical contact with one another characterised in that at least one phase comprises polyacrylate-1 crosspolymer and one phase is a conditioning gel phase. | 2013-01-03 |
20130004452 | Formulations Containing an Ionic Mineral-Ion Exchange Resin Complex and Uses Thereof - A process for preparing a formulation comprising a complex comprising an effective amount of ferrous iron bound to a pharmaceutically acceptable cationic resin and at least one pharmaceutically acceptable carrier is described. Such a formulation may optionally include other desirable dietary supplements including, e.g., vitamins, omega fatty acids, and/or fluoride. The formulation is particularly well adapted for pediatric use, but is also useful for use in adult populations. | 2013-01-03 |
20130004453 | NYLON-3 CO-POLYMERS AND SYNTHETIC LUNG SURFACTANT COMPOSITIONS CONTAINING SAME - Non-natural oligomers have recently shown promise as functional analogues of lung surfactant proteins Band C (SP-B and SP-C), two helical and amphiphilic proteins that are clitical for normal respiration. The generation of non-natural mimics of SP-B and SP-C has previously been restlicted to step-by-step, sequence-specific synthesis, which results in discrete oligomers that are intended to manifest specific structural attributes. Presented herein an alternative approach to SP-R mimicry that is based on sequence-random copolymers containing cationic and lipophilic subunits. These materials, members of the nylon-3 family, arc prepared by ling-opening polymelization of 13-lactams. The best of the nylon-3 polymers display promising in vitro surfactant activities in a mixed lipid film. Pulsating bubble surfactometry data indicate that films containing the most surface-active polymers attain adsorptive and dynamic-cycling properties that surpass those of discrete peptides intended to mimic SP-B. | 2013-01-03 |
20130004454 | POLYURETHANE BLOCK COPOLYMER BASED ON POLY SILOXANE TENSIDE FOR MEMBRANES - Oligo- or polyurethane compounds of the formula (I) wherein k and n independently are numbers from 1 to 100, m is from the range 1-100, (X) is a block of formula (II) and (Y) is a block of the formula (III), (A) is a residue of an aliphatic or aromatic diisocyanate linker, (B) is a residue of a linear oligo- or polysiloxane containing alkanol end groups, and optionally further containing one or more aliphatic ether moieties, and (C) is an aromatic oligo- or polysulfone block, may advantageously be used as anti-adhesion additives in polymer compositions e.g. for membranes; related oligo- or polyurethanes wherein m is 0 are especially suitable for the preparation of antimicrobial water separation membranes. | 2013-01-03 |
20130004455 | POLY(ORGANOPHOSPHAZENE) COMPOSITION FOR BIOMATERIALS - Provided are a use of chemically-crosslinkable, poly(organophosphazene)s for biomaterials, chemically-crosslinkable poly(organophosphazene)s with a physiologically active substance covalently-bonded thereto, a use thereof for biomaterials, and a process for preparing the same. The chemical crosslinkings can be made by UV irradiation, and/or a crosslinker, and/or an additive, and/or an enzyme, and/or a mixing of at least one polymer. | 2013-01-03 |
20130004456 | COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas. | 2013-01-03 |
20130004457 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2013-01-03 |
20130004458 | Small Molecule Inhibitors of Retroviral Assembly and Maturation - Chemical compounds that disrupt retroviral assembly and maturation are presented herein. More particularly, this disclosure provides small molecule compounds that disrupt the formation and maturation of virus particles and methods of using such small molecules to treat HIV-1 infection. | 2013-01-03 |
20130004459 | METHODS, PHARMACEUTICAL COMPOSITIONS AND KITS FOR USE IN THE TREATMENT OF ADULT T-CELL LEUKEMIA/LYMPHOMA - The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma. | 2013-01-03 |
20130004460 | SILYLATED BIOMOLECULES - The invention concerns: a silylated biomolecule having the following formula (I): the process for the preparation of a silylated biomolecule of formula (I), the use of a silylated biomolecule of formula (I) to functionalize the surface of a support, a process for the preparation of a hydrogel by use of a silylated biomolecule of formula (I), the hydrogel obtainable by said process, said hydrogel as a biological tissue substitute, a composition comprising said hydrogel in a pharmaceutically acceptable vehicle, said composition for the release of active principle. | 2013-01-03 |
20130004461 | SUBFAMILY E SIMIAN ADENOVIRUSES A1321, A1325, A1295, A1309, A1316 AND A1322 AND USES THEREOF - Recombinant vectors comprise simian adenovirus A1321 (SAdV-A1321), SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1321, SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided. | 2013-01-03 |
20130004462 | MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY - The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia. | 2013-01-03 |
20130004463 | DNA DAMAGE REPAIR PROMOTER FOR ORAL APPLICATION, AND ELASTASE ACTIVITY INHIBITOR FOR ORAL APPLICATION - To provide a DNA damage repair promoter for oral application and an elastase activity suppressor for oral application. | 2013-01-03 |
20130004464 | MULTIPOTENT ADULT STEM CELL POPULATION - The present invention relates to the identification, isolation, expansion and characterization of a specific type of adult stem cell. These adult stem cells are characterised in that they naturally express many of the markers of totipotency, which have hitherto generally been limited to embryonic cell populations. The cells of the invention display an unprecedented capacity for multipotency; they are able to differentiate into cell types of mesodermal, endodermal and ectodermal origin. These adult stem cells may be used as therapeutic agents including, without limitation, for the regeneration of tissue, particularly for regeneration of damaged cardiac tissue, such as myocardium. | 2013-01-03 |
20130004465 | ADHERENT CELLS FROM PLACENTA AND USE OF SAME IN DISEASE TREATMENT - Methods for treating conditions by administration of placenta derived adherent stromal cells to a subject in thereof are provided. Such conditions include skeletal muscle defects, neuropathic pain, and myocardial infarction. Also provided are methods wherein the adherent stromal cells administered are cultured under 2 dimensional or 3 dimensional growth conditions. Also provided are methods in which the cells administered are at least 70% adherent cells from a maternal or fetal portion of the placenta. | 2013-01-03 |
20130004466 | MYOGENIC DIFFERENTIATION OF STEM CELLS AND AND USES THEREOF - Disclosed are methods of differentiating stem cells into muscle cells by growing the cells in a myogenic culture medium. The differentiated cells can be used as a source of cells for transplantation in a patient in need thereof. | 2013-01-03 |
20130004467 | MYELINATION OF CONGENITALLY DYSMYELINATED FOREBRAINS USING OLIGODENDROCYTE PROGENITOR CELLS - One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. | 2013-01-03 |
20130004468 | METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOF - The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation. | 2013-01-03 |
20130004469 | ENGINEERED LUMENIZED VASCULAR NETWORKS AND SUPPORT MATRIX - Disclosed herein are capillary fabrication devices comprising living cells within a support medium. Culture of the cells produces viable lumenized capillary networks with natural or pre-determined geometries and ECM and basement membrane associated with the capillary networks. The capillary networks and the ECM and basement membrane detachable from the capillary networks are useful for tissue engineering applications. | 2013-01-03 |
20130004470 | p27 AND p21 IN GENE THERAPIES - The expansion of a population of stem cells or progenitor cells, or precursors thereof, may be accomplished by disrupting or inhibiting p21 | 2013-01-03 |
20130004471 | GENE THERAPY VECTORS FOR ADRENOLEUKODYSTROPHY AND ADRENOMYELONEUROPATHY - The present invention provides compositions comprising retroviral vectors, transduced cells, and methods of using the same for gene therapy. In particular, the present invention relates to lentiviral vectors and cells transduced with those vectors to provide gene therapy to subjects having an adrenoleukodystrophy and/or adrenomyeloneuropathy. | 2013-01-03 |
20130004473 | Methods and Biomarkers for the Detection of Dengue Hemorrhagic Fever - The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF. | 2013-01-03 |
20130004474 | SOLUBLE PHYSIOLOGICAL CHITOSAN FORMULATIONS COMBINED WITH PLATELET-RICH PLASMA (PRP) FOR TISSUE REPAIR - The present disclosure relates to an activated polymer composition for use in repairing tissue of a patient comprising platelet-rich plasma (PRP), a chitosan solution, a salt such as NaCl or glycerol phosphate, and an activator such as at least one of CaCI | 2013-01-03 |
20130004475 | AGENT FOR INCREASING BIFIDOBACTERIA AND REDUCING THE DECREASE OF BIFIDOBACTERIA IN LARGE INTESTINE - The present invention provides a means and a method for effectively increasing Bifidobacteria in the large intestine. Specifically, the present invention relates to an agent for increasing Bifidobacteria and/or reducing the decrease of Bifidobacteria in the large intestine, which comprises spores of | 2013-01-03 |
20130004476 | Chimeric Polypeptides and Their Use in Bacterial Decolonization - The present invention relates to chimeric polypeptides comprising a first portion, which comprises a bacteriocin cell wall-binding domain (CBD) and a second portion, which comprises an enzymatic active domain (EAD) selected from the lytic domain of a bacteriophage lysin, a bacteriocin and a bacterial autolysin. Provided are such chimeric polypeptides and variants and fragments thereof, nucleic acids encoding the same, vectors carrying such nucleic acids and host cells transformed or transfected with such vectors. The chimeric polypeptides of the present invention are useful for the reduction of certain bacterial populations, including methods and compositions for the treatment of various bacterial infections. For example, chimeric polypeptides of the present invention have been shown to effectively kill various bacteria, including methicillin-resistant | 2013-01-03 |
20130004477 | Methods for Treating Inflammation and Oxidative Stress Related Diseases - This invention provides compositions and methods for treating inflammation related diseases. Particularly, the present invention provides methods and compositions of administering thiocyanate to treat inflammation related diseases, such as cystic fibrosis, lung disease, lung cancer, asthma, bronchitis, pancreatic disease, digestive track disease, diabetes, neurological disorder, cardio-vascular disease, atherosclerosis, arthritis, nephritis, or stroke, and neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, or autism. The invention provides the use of thiocyanate to diagnose inflammation related diseases. | 2013-01-03 |
20130004478 | Procoagulant Peptides and Their Derivatives and Uses Therefor - The present invention is directed to a hemostatic or tissue sealing material having (a) a peptide having a sequence SEQ ID NO: 1 or an amino acid analog sequence thereof, and (b) a scaffold for said peptide or amino acid analogue sequence. The scaffold is preferably hemostatic, such as a natural or genetically engineered absorbable polymer, a synthetic absorbable polymer, or combinations thereof. The natural or genetically engineered absorbable polymers can be selected from the group consisting of a protein, a polysaccharide, or combinations thereof. | 2013-01-03 |
20130004479 | ENZYMATIC PERACID GENERATION FORMULATION - Disclosed herein are multi-component formulations for enzymatically producing aqueous solutions of peroxycarboxylic acids suitable for use in, e.g., disinfectant and/or bleaching applications. The multi-component peroxycarboxylic acid formulations comprise at least one carbohydrate esterase family 7 enzyme having perhydrolytic activity. | 2013-01-03 |
20130004480 | CD20 Binding Molecules for the Treatment of Copd - Use of CD20 binding molecules, such as anti-CD20 antibodies, for the treatment of chronic obstructive pulmonary disease (COPD). | 2013-01-03 |
20130004481 | ANTICANCER THERAPY - The invention describes anti-cancer therapies comprising using dual Aurora kinase/MEK inhibitors as described herein. | 2013-01-03 |
20130004482 | Methods of Treating Breast Cancer with Anthracycline Therapy - The application describes methods for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including an anthracycline. The application also describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including anthracycline and administering the therapy in subjects when it is found that anthracycline is likely to be effective. | 2013-01-03 |
20130004483 | MEDICAL METHODS AND AGENTS FOR USE THEREIN - The present invention provides an immunomodulatory agent for use in the local treatment of tumours, wherein the treatment comprises patient-specific optimisation of the dose of the immunomodulatory agent to identify the maximum therapeutic dose that does not induce an increase in the number of local regulatory T cells (Treg cells) in the patient The invention further provides methods for the local treatment of tumours as well as methods for optimising treatments for the same | 2013-01-03 |
20130004484 | ANTI-C-MET ANTIBODY FORMULATIONS - Provided herein are pharmaceutical formulations comprising a one-armed, anti-c-met antibody and uses of the same. | 2013-01-03 |
20130004485 | HUMANIZED AND CHIMERIC ANTI-PROPERDIN ANTIBODIES - An isolated anti-properdin antibody or antigen binding portion thereof includes a heavy chain variable domain including the 3CDRs in SEQ ID NO: 1 and light chain variable domain including the 3 CDRS in SEQ ID NO: 9. | 2013-01-03 |
20130004486 | TREATMENT OF VASCULARIZED PIGMENT EPITHELIAL DETACHMENT WITH ANTI-VEGF THERAPY - Methods for treating vascularized pigment epithelial detachment using anti-VEGF agents are disclosed. | 2013-01-03 |
20130004487 | SCD40L AND PLACENTAL GROWTH FACTOR (PIGF) AS BIOCHEMICAL MARKER COMBINATIONS IN CARDIOVASCULAR DISEASES - The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools that facilitate the selection of active ingredients for the treatment of such diseases, and finally act as starting points for the treatment of cardiovascular diseases. Furthermore, the invention relates to the creation of an individual risk profile of negative events that are associated with the progression of arteriosclerosis. | 2013-01-03 |
20130004488 | ANTI-CANCER AGENT DELIVERY VEHICLES CAPABLE OF IMPROVED LOADING - There is provided a conjugate of a delivery agent containing a chemical moiety and at least one flavonoid. The flavonoid exists in a monomeric form or dimeric form before conjugation and remains in the monomeric form or dimeric form after conjugation. Preferably, the conjugate comprises two flavonoids. The delivery agent is conjugated at the C6 and/or the C8 position of the A ring of the flavonoid. An anti-cancer agent delivery vehicle comprising an anti-cancer agent and the conjugate is also provided. | 2013-01-03 |
20130004489 | ACTIVIN-ACTRIIA ANTAGONISTS AND USES FOR TREATING MULTIPLE MYELOMA - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. | 2013-01-03 |
20130004490 | DELIVERY OF TRANSTHYRETIN ACROSS THE BLOOD-BRAIN BARRIER AS A TREATMENT FOR ALZHEIMER'S DISEASE - The invention provides a composition comprising transthyretin and an ICAM-1 targeting agent, wherein the transthyretin and ICAM-1 targeting agent are coupled together, as well as methods of preparing such compositions. The invention further provides a diabody capable of binding specifically to ICAM-1 and transthyretin. The invention also provides a method of use of such composition in the manufacture of a medicament for treating an amyloid-β related neurodegenerative disease, comprising administering to a subject a composition comprising transthyretin coupled to an ICAM-1 targeting agent in an amount effective to treat the neurodegenerative disease, wherein the composition is administered to the subject outside of the blood-brain barrier. | 2013-01-03 |
20130004491 | Antibodies Against Phosphorylcholine In Combination Therapy with Biologic Agents - Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells. | 2013-01-03 |
20130004492 | FGFR EXTRACELLULAR DOMAIN ACIDIC REGION MUTEINS - Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided. | 2013-01-03 |
20130004493 | EPITHELIAL MEMBRANE PROTEIN-2 (EMP2) AND PROLIFERATIVE VITRORETINOPATHY (PVR) - Methods of preventing retinal detachment associated with proliferative vitreoretinopathy are provided by administering agents which antagonize the activity or function of EMP2 to subjects at risk of the detachment. | 2013-01-03 |
20130004494 | Inhibition of P21 and Use Thereof for Inducing Tissue Regeneration - The present invention embraces a method for inducing tissue regeneration using a p21 inhibitor as well as a bio-compatible tissue engineering product containing a p21 inhibitor. | 2013-01-03 |
20130004495 | ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS - The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including pain, asthma, arthritis and psoriasis. The methods are effective in treating these disorders in a patient without having a significant adverse effect on the immune system of the patient. | 2013-01-03 |
20130004496 | MONOCLONAL ANTIBODIES SPECIFIC TO HEMAGGLUTININ AND NEURAMINIDASE FROM INFLUENZA VIRUS H5-SUBTYPE OR N1-SUBTYPE AND USES THEREOF - Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1 subtypes and provide means for the diagnosis, surveillance and treatment of dangerous viral infections. | 2013-01-03 |
20130004497 | MONOCLONAL ANTIBODIES SPECIFIC TO HEMAGGLUTININ AND NEURAMINIDASE FROM INFLUENZA VIRUS H5-SUBTYPE OR N1-SUBTYPE AND USES THEREOF - Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1 subtypes and provide means for the diagnosis, surveillance and treatment of dangerous viral infections. | 2013-01-03 |
20130004498 | DOSING FOR TREATMENT WITH ANTI-EGFL7 ANTIBODIES - The present invention concerns dosing of anti-EGFL7 antibodies for cancer therapy. | 2013-01-03 |
20130004499 | ANTIBODY AGAINST SEROTYPE E LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 2013-01-03 |
20130004500 | ANTIBODY AGAINST SEROTYPE A LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 2013-01-03 |
20130004501 | HUMAN IL-23 ANTIGEN BINDING PROTEINS - Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided. | 2013-01-03 |
20130004502 | INFLUENZA TARGETS - The present invention relates to a pharmaceutical composition comprising an inhibitor of influenza virus replication. Yet another aspect is a screening method for identification of new targets for the prevention, alleviation or/and treatment of influenza. | 2013-01-03 |
20130004503 | ENGINEERED ANTI-TSLP ANTIBODY - The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders. | 2013-01-03 |
20130004504 | METHOD OF MODULATING PHENYLALANINE HYDROXYLASE STRUCTURE AND FUNCTION - A method of affecting a multimeric protein comprising an equilibrium of assembly states, each assembly having a plurality of units, wherein each of the units comprises a first complementary surface and a second complementary surface and wherein the first complementary surface of one unit is associated with the second complementary surface of another unit, provided that the assembly is at least one of different quaternary isoforms under four conditions, wherein the method comprising: applying to the multimeric protein a composition comprising a compound adapted to affect formation of an active form of the multimeric protein; associating the composition with an active form of the multimeric protein; and promoting the multimeric protein to assemble into the active form, thereby affecting the multimeric protein to form the active form, wherein the multimeric protein is phenylalanine hydroxylase. | 2013-01-03 |
20130004505 | HUMAN MONOCLONAL ANTIBODIES DERIVED FROM HUMAN B CELLS AND HAVING NEUTRALIZING ACTIVITY AGAINST INFLUENZA A VIRUSES - The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection. | 2013-01-03 |
20130004506 | METHOD FOR TREATING PATHOLOGIES ASSOCIATED WITH HYPOXIA USING MIF INHIBITORS - Methods are provided for treating pathologies associated with hypoxia with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk for pulmonary hypertension, with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk from, a CNS disorder associated with hypoxia, with an MIF inhibitor. Methods are also provided of treating severe chronic lung disease, hypoxia-induced right ventricular hypertrophy or hypoxia-induced pulmonary vascular remodeling with an MIF inhibitor. Methods of diagnosing a subject with pulmonary hypertension are also provided. | 2013-01-03 |